Impact of natural menopause on multiple sclerosis: a multicentre study
Damiano Baroncini, Mauro Zaffaroni(Associazione Italiana Sclerosi Multipla), Paolo Confalonieri(Fondazione IRCCS Istituto Neurologico Carlo Besta), Caterina Barrilà, Valentina Torri Clerici, Marco Ronzoni(ATS Sardegna (Italy)), Maria Letizia Fusco(Azienda Ospedaliera San Gerardo), Giulia Mallucci, Ruggero Capra(Presidio Ospedaliero), Raffaella Clerici(CTO Hospital), Luca Chiveri(Azienda Ospedaliera Ospedale Civile di Legnano), Valeria Barcella, Simone Tonietti(Ospedale San Carlo), Ottavia Eleonora Ferraro(University of Pavia), M Messina(Vita-Salute San Raffaele University), Emanuela Susani, Elena Colombo, Maria Teresa Ferrò(Hospital Universitario Ramón y Cajal), Lucia Abate(Azienda Socio Sanitaria Territoriale della Valtellina e Alto Lario), Pietro Annovazzi(Vita-Salute San Raffaele University), Nicola De Rossi, Vittorio Mantero(Aziende Socio Sanitarie Territoriali di Lecco)
Cited by 70
Related Papers
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
|New England Journal of Medicine|2010|2.2k
Pathophysiology of COVID-19-associated acute respiratory distress syndrome: a multicentre prospective observational study
|The Lancet Respiratory Medicine|2020|738
Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN)
|The Lancet|2002|552
Brain atrophy and lesion load predict long term disability in multiple sclerosis
|Journal of Neurology Neurosurgery & Psychiatry|2013|327
Multiple sclerosis in childhood: clinical features of 149 cases
|Multiple Sclerosis Journal|1997|309